Hypertension in diabetes is an important and treatable cardiovascular risk factor. Treatment targets from guidelines cannot always be achieved in everyday clinical practice. It is therefore of great importance to monitor trends in hypertension control in defined populations. Patients with type I diabetes (range 6685-10 100; treated hypertension 21-29%) or with type II diabetes (range 15 935-22 605; treated hypertension 47-56%) were included in four national samples between 1996 and 1999. This screening was part of the procedures for the National Diabetes Register in Sweden, which monitors trends in clinical practice and risk factors for patients with diabetes, recruited both in primary health care and at the hospital level. A favourable trend in mean and median blood pressure levels was noticed during the 4-year study period, based either on data from repeated surveys or on repeated measures in the same individual, both for type I diabetes (mean: À2/À2 mmHg; Po0.01) and for type II diabetes (mean: À5/À3 mmHg; Po0.001). Correspondingly, the proportion of hypertensive patients in acceptable control of blood pressure (p140/ 85 mmHg) increased (Po0.001) both in type I diabetes (52.0-57.9%) and in type II diabetes (22.4-33.3%). It was concluded that hypertension is a widespread cardiovascular risk factor in patients with diabetes, especially systolic hypertension. A trend for a better systolic blood pressure control during the late 1990s in hypertensive patients with type II diabetes in Sweden could translate into substantial (estimated) clinical benefits in cardiovascular and diabetes-related morbidity. The National Diabetes Register makes a quality assessment of the hypertension treatment possible.
Introduction
Hypertension is a common and important cardiovascular risk factor in diabetes mellitus, with major implications not only for increased morbidity and mortality 1 but also for health care costs. 2 International guidelines have repeatedly stressed the importance of hypertension control in all patients with diabetes. [3] [4] [5] [6] These guidelines are based on published data from several randomised intervention studies performed in both type I diabetes 7 and type II diabetes, such as the United Kingdom Prospective Diabetes Study (UKPDS) 8 and Hypertension Optimal Treatment (HOT) study. 9 These large-scale studies have proven the clinical benefits of tight blood pressure control for renal protection and prevention of cardiovascular events in patients with diabetes.
However, in the diabetic population at large, the level of blood pressure control is often far from optimal, as the standards of care delivered in clinical studies cannot always be achieved outside the study settings. It is therefore of interest to compare population-based data from repeated national surveys, in order to investigate if clinical practice in hypertension management and care has changed during recent years as measured by changes in mean/median blood pressure levels as markers of hypertension control. A change for the better in blood pressure control could be anticipated because of the possible influence of new treatment guidelines [3] [4] [5] [6] and the important UKPDS findings. 8 This has so far not been proven in national studies.
According to an observational analysis of changes in median blood pressure levels in the UKPDS, a decrease of 10 mmHg in mean in-study systolic blood pressure levels corresponds, for example, to a reduction of 12% for any complications related to diabetes, 15% risk reduction for deaths related to diabetes, 11% for myocardial infarction, and 13% for microvascular complications. 10 These analyses of observational outcome data from the UKPDS 10 have now been applied to findings in treated hypertensive diabetes patients from Sweden, as reported in this study.
The aim was to use data from the National Diabetes Register of Sweden to evaluate trends in hypertension control in treated patients during the period 1996-1999, based on a total number of 146 036 patients with diabetes available in the register. Our hypothesis was that improvements in blood pressure control should be detected following the recommendations from current international and national guidelines.
Subjects and methods

Register of diabetes patients
A National Diabetes Register (NDR) was launched in Sweden in 1996 aiming for the registration of demographic data, diabetes duration, treatment modalities, and risk factors in consecutive diabetic patients followed in primary health care (PHC) or at the hospital level. The rationale for the NDR was to implement the principles of the St Vincent declaration 11 for quality improvements in diabetes care on a national scale. The background of the NDR and the rationale for the register has been extensively described in another report (S Gudbjö rnsdottir et al, Abstract EASD 2002).
During each year (1996) (1997) (1998) (1999) , the clinical data provided to the NDR have been collected centrally, and then redistributed to the providers, showing aggregated data of each hospital or health centre as compared to national means. The aim for this routine has been to support a process of quality assurance and development of diabetes care at the local level. In all, a total of 27 213 (1996), 41 154 (1997), 36 518 (1998), and 41 151 (1999) patients with diabetes were registered within the NDR. These numbers of patients constitute four separate (independent) samples of the total diabetes population in Sweden.
Our data represent approximately 75% of all hospital outpatient diabetic patients (58 participating hospitals out of 80), and approximately 15% of the total number of diabetic patients in PHC. Data were collected from all parts of Sweden, for example, at 162 PHC centres in 1996, 174 centres in 1998, 139 centres in 1998, and 141 centres in 1999, out of a total of nearly 900 health centres. Only adult patients were registered (418 years old).
Definitions of study participants
In this report we wanted to focus on patients with type I and type II diabetes with antihypertensive treatment, irrespective of the health care level.
We defined type I diabetes as the onset of diabetes before the age of 30 years in combination with insulin treatment. The corresponding definition of type II diabetes was onset of diabetes after the age of 40 years irrespective of the type of treatment. This means that all patients with diabetes onset between 30 and 40 years, as well as all patients with diabetes onset before the age of 30 years on oral treatment or on combined oral and insulin treatment were excluded from further analyses. Furthermore, some patients also had to be excluded because of missing data regarding onset age of diabetes or hypertension treatment. The excluded numbers of NDR patients were 4593 (1996), 8449 (1997), 6308 (1998), and 11 481 (1999) .
Diabetic nephropathy (DN) was defined as the constant finding of albuminuria (4300 mg/day) or elevation of serum creatinine (4150 mmol/l).
Of all eligible type I and type II diabetic patients in NDR, in all 9496 (1996), 12 954 (1997), 12 838 (1998), and 13 995 (1999) patients were reported to have treated hypertension, and thus form the study population for the analyses of trends in blood pressure control.
Definition and treatment recommendations of hypertension in diabetes
The definition and decision to treat hypertension was based on clinical judgement on an individual basis, and may have varied locally and over time. This decision was, however, in most cases expected to have been based on the national recommendations from the early 1990s to treat blood pressure 4140/90 mmHg in type I diabetes and 4160/ 95 mmHg in type II diabetes (Medical Products Agency, Uppsala, Sweden, 1990). These definitions may seem conservative today. The role of lifestyle intervention has been highlighted in previous recommendations, but in almost all cases an additional drug treatment had normally been started, either in mono-or combination therapy. All major classes of antihypertensive drugs are licensed for use in patients with diabetes in Sweden. By tradition, selective beta-receptor blockers have always had a very important role in hypertension treatment in Sweden also in diabetic patients, 12 but diuretics, ACE inhibitors, calcium antagonists, and recently the angiotensin-II receptor blockers are also widely used. No registration of specific drug treatment categories has so far been included in the NDR.
Clinical investigations
Diabetic patients were screened by use of local methods and blood pressure devices. A standard recommendation for blood pressure recordings has been published in Sweden (Medical Products Agency, Uppsala, Sweden, 1990), stating that a mean of two readings (mmHg) in the supine position shall be recorded after 10 min of rest, using a cuff of appropriate size. These recommendations were further endorsed by instructions from NDR. In Sweden, normally the use of Korotkoff sound I is used for definition of systolic blood pressure and Korotkoff V for definition of diastolic blood pressure. The pulse pressure was calculated as the difference between systolic and diastolic blood pressure levels. Other clinical variables such as glycaemic control (HbA 1c ), body mass index (BMI), smoking, and diabetes duration were also registered, and data regarding these variables among all diabetes patients have been discussed separately (S Gudbjö rnsdottir et al, Abstract EASD 2002).
Statistical methods
We calculated means and standard deviation (s.d.), as well as median levels, for systolic and diastolic blood pressure. Mean levels of the variables were statistically compared between the first year (1996) and the last year (1999) of registrations using a Student's t-test for unpaired (independent) samples of diabetes patients, separated into type I and type II diabetes. In addition, we also made similar analyses in a subsample of patients with repeated individual measurements in the same subject, using a paired t-test. A w 2 -test was used to compare proportions. A P-value less than 0.05 was considered to be significant.
Results
Blood pressure control in treated hypertensive patients with diabetes
Among type I diabetes patients, the total proportion of treated hypertension increased from 20.9% in 1996, 23.1% in 1997, 23 .3% in 1998, to 29.4% in 1999 (Po0.0001). The corresponding proportions of type II diabetes patients with treated hypertension were 50.8, 47.0, 51.7, and 56.3% (Po0.0001) for the years 1996-1999, respectively (Table 1) .
A decreasing trend for mean systolic and diastolic blood pressure was reported between 1996 and 1999 for both type I and type II diabetes patients with treated hypertension (Po0.01-001), and for mean pulse pressure in treated type II diabetes (Po0.0001) ( Table 2 ). The decrease in blood pressure was À2/À2 mmHg for type I and À5/À3 mmHg in type II diabetes patients between 1996 and 1999.
The proportions of type I diabetes patients with treated hypertension who were well controlled (p140/85 mmHg) consisted of 52.0% (1996), 55.4% (1997), 55.5% (1998), and 57.9% (1999), with a significantly increasing trend (Po0.001) ( Table 2) . Correspondingly, the proportions of type II diabetes patients with treated hypertension who were well controlled, during 1996-1999 according to UKPDS standards of a level p140/85 mmHg, were 26.9% (1996), 31.8 % (1997), 33.1% (1998), and 36.3% (1999), with a significantly increasing trend (Po0.0001) ( Table 2) . Similarly, proportions of type II diabetes patients with treated hypertension in optimal control (o130/85 mmHg) increased significantly from 1996 to 1999: 5.8, 7.1, 7.9, and 9.4% (Po0.001).
If only patients with repeated individual blood pressure recordings were included in the analyses, the favourable improvement in blood pressure control was significant for both type I (n ¼ 586) and type II (n ¼ 3329) diabetes (Table 3) .
Changes of HbA 1c and BMI
The decreases of mean HbA 1c during 1996-1999 were significant in both type I (median values 7.7-7.4%) and type II diabetes (median values 6.8-6.5%) patients with treated hypertension (Po0.001). This was also found for the increases during 1996-1999 in proportions of patients with HbA 1c o6.5% in treated type I (12.8-19 .8%) and in treated type II (Table 4 ).
Blood pressure control in treated patients with diabetes and nephropathy
The proportion of patients with nephropathy, with or without treatment for hypertension, increased over time in both type I and type II diabetes. An improved blood pressure control over time was however only recorded in type II, but not in type I diabetes patients with nephropathy (Table 5) . 
Discussion
The implementation in 1996 of the NDR in Sweden served several purposes. One was to emphasise the principles of good quality in diabetes care, as outlined in the St Vincent declaration, 11 another purpose being the surveillance of trends in clinical practice and risk factor management, including the important aspect of evaluation and treatment of hypertension in diabetes. In this first report on trends in hypertension control we have focused on the subgroups of treated hypertensive patients with either type I or type II diabetes, recruited from four independent samples of data from registered patients during 1996-1999. Also data from repeated measurements in the same individuals have been used. This is therefore a more focused analysis as compared to another report on data and changes in mean levels based on all registered patients within the NDR (S Gudbjö rnsdottir et al, Abstract EASD 2002).
The two main findings of this report to be discussed are the following: Firstly, a diagnosis of treated hypertension is reported in more than half of all type II diabetes patients (56.3% in 1999), as well as in about a third of all patients with type I diabetes (29.4% in 1999). Secondly, a favourable trend in decreasing median levels of systolic blood pressure between 1996 and 1999 was observed in both type I (À2/À2 mmHg) and type II (À5/À3 mmHg) diabetes patients with treated hypertension. This was recorded both after analysis of trends in the independent samples or based on repeated recordings over time in the same individuals, in spite of the increasing BMI trend in patients with type II diabetes.
Epidemiology of treated hypertension in diabetes
The high proportion of diabetic patients with concomitant treated hypertension is in accordance with other population-based studies on the screening of newly detected type II diabetes 13 or patients with established disease. 14 The corresponding proportion of type I diabetes patients with treated hypertension was also in accordance with previous studies. However, a possible bias could be that the participating centres in the NDR might have shown a higher ambition for screening, diagnosing, and treating hypertension, as compared to other centres. Our proportion of patients with treated hypertension is, however, in accordance with other Swedish screening studies based on clinical practice. 14, 15 One factor beyond complete standardisation is the variations in local practice at various hospitals or PHC centres related to cutoff points for defi- nition, diagnosis, and treatment of hypertension. In Sweden, previous attempts were made in 1990 to give national recommendations for the management of hypertension in diabetes, which might have supported the standardisation of diagnostic procedures and care.
Trends in blood pressure control
In the UKPDS, the observation of a near-linear association between median in-study systolic blood pressure levels and complications enabled the investigators to estimate the potential health benefits of a decrease in systolic blood pressure of 10 mmHg. 10 This calculation showed that 11-15% of complications could be expected to have been prevented by this change in mean blood pressure levels. However, the interpretation of results also indicated that these benefits seemed to be even more pronounced in the treated hypertensive patients who participated in the randomised intervention study on tight blood pressure control within the UKPDS. 10, 16 In other words, the clinical benefits were also attributed to other positive influences 17, 18 of the antihypertensive drugs used (beta-receptor blocker, ACE inhibitor), independent of the blood pressure reduction achieved. When we calculated the estimated health benefits associated with a decrease of À5 mmHg systolic blood pressure between 1996 and 1999 in Swedish type II diabetic patients, based on the UKPDS findings, we noticed similar trends. Reductions were thus calculated to be À6% in any diabetes complications, À8% in diabetes-related deaths, À6% in myocardial infarctions, and À7% in microvascular complications, as a conservative estimation based on UKPDS predictions in all diabetes patients. This seems impressive on the population level, but could the interpretation of data also be criticised?
The age distribution was not identical between our study and the UKPDS. Furthermore, in the UKPDS all patients had a newly detected type II diabetes, but in our study the diabetes duration was 8 years (median). Additionally, a favourable trend in median systolic blood pressure levels over time could not only be due to intensified treatment and more effective drugs, often used in combination therapy in the post-UKPDS era, but also potentially to decreasing blood pressure levels in the population at large. 19, 20 Another factor could be the possible inclusion over time of increasing proportions of patients with milder diabetes via modern screening procedures. On the other hand, these findings are in accordance with similar trends in blood pressure control in hypertensive patients at large both in the UK 21 and in Sweden. 22 We have no reason to believe that blood pressure measurement techniques have changed during the observation period. Longitudinal data based on repeated blood pressure measurements in individual patients in the NDR support the notion that blood pressure control has significantly improved between 1996 and 1996 ( Table 3) .
Proportion of patients in optimal hypertension control
The proportion of patients reaching the treatment goal according to UKPDS standards (p140/ 85 mmHg) also showed clearly increasing trends of improvement in both type I and type II diabeties patients during this 4-year period of NDR. However, it should be pointed out that this goal was achieved in only one-third of the type II diabetes patients, which was mostly because of the low frequency of achieved systolic blood pressure p140 mmHg. Furthermore, the treatment goal set by the Joint European Societies of Cardiology, Atherosclerois and Hypertension, 3 o130/85 mmHg, was achieved in only 10% of type II diabetes patients, although the Joint Committee underlines that less ambitious goals have to be accepted in elderly patients. Systolic hypertension has been defined by WHO/ ISH Hypertension Practice Guidelines (1999) as blood pressure X140/o90 mmHg. 4 In this study, we found that systolic blood pressure levels in as much as half of the treated hypertensive type II diabetes patients are still elevated.
The results in the present study strengthen the importance of hypertension as a major risk factor in type II diabetes. In combination with the data on benefits associated with systolic blood pressure decrease from the UK, 10, 23 this supports the notion that hypertension control, and especially systolic hypertension control, should be a main target for the management of patients with type II diabetes. As no lower threshold for benefits in relation to systolic blood pressure has been shown in the UKPDS, 10 at least in the systolic blood pressure range 120-160 mmHg, this implies that there are reasons to do even more in order to control systolic hypertension. Lower target levels of blood pressure control in type II diabetes patients (o130/80 mmHg) may thus be argued for, as was recently presented by the American Diabetes Association. 24 The use of newer drugs, often in combination therapy with older drugs, could make this goal achievable as was recently demonstrated in the diabetes substudy of the LIFE trial. 25 Lipid levels have until now not been reported in the NDR. In a more updated version of NDR, these variables will however now be included (from 2002 onwards), making it possible to calculate the trends in lipid variables for future reports.
In conclusion, based on the data from repeated national surveys of type I and type II diabetes patients, it was shown that the prevalence of treated hypertension is high and that the level of blood pressure control is far from optimal. However, the trend in hypertension control during the late 1990s suggests a modest improvement over time, which corresponds to improved cardiovascular risk and a reduction of estimated clinical complications. Further cross-sectional data from the NDR in the years to come should enable us to reveal if this favourable trend will continue or not. The current findings imply that systolic hypertension in diabetes patients should be more vigorously treated than has often been achieved in the past.
